Clinical Scorecard: CAR T-Associated Enterocolitis Involves Multiple Intestinal Inflammatory Changes
At a Glance
| Category | Detail |
|---|---|
| Condition | CAR T-associated enterocolitis (CAR-TEC) after BCMA-directed CAR T-cell therapy |
| Key Mechanisms | Intestinal inflammation involving T cells, myeloid cells, stromal cells, and epithelium; findings included cytotoxic and inflammatory CAR T cells and activation of interferon and JAK–STAT signaling. Some cases lacked detectable mucosal CAR T-cell infiltration. |
| Target Population | Patients with multiple myeloma who developed enterocolitis after BCMA-directed CAR T-cell therapy |
| Care Setting | Single-cell and tissue-based analyses of intestinal samples from patients with CAR-TEC |
Key Highlights
- CAR-TEC was associated with inflammatory changes across multiple intestinal cell types, not only B-cell and plasma-cell depletion.
- Some patients without enterocolitis had similarly profound B-cell and plasma-cell depletion.
- CAR T cells were detected in intestinal tissue more than 2 years after infusion in one patient, despite being undetectable in peripheral blood or bone marrow.
- Some patients had no detectable mucosal CAR T-cell infiltration, indicating that persistent mucosal CAR T cells were not detected in every reported case.
- Two patients treated with upadacitinib showed improvements in symptoms, fecal calprotectin, and body weight within 4 weeks.
Guideline-Based Recommendations
Diagnosis
- The study characterized intestinal samples using single-cell and tissue-based analyses.
Management
- Two patients received the selective JAK1 inhibitor upadacitinib; the report describes clinical and biomarker improvements within 4 weeks.
Monitoring & Follow-up
- In one patient analyzed after upadacitinib treatment, intestinal CAR T-cell density decreased from 193 to 39 cells per high-power field.
- Reported measures included symptoms, fecal calprotectin, body weight, and intestinal tissue and immune findings.
Risks
- CAR-TEC is described as a rare but serious gastrointestinal complication of BCMA-directed CAR T-cell therapy.
- The study does not establish that persistent mucosal CAR T cells cause all cases of enterocolitis.
Patient & Prescribing Data
Patients with multiple myeloma who developed CAR-TEC after BCMA-directed CAR T-cell therapy; two patients received upadacitinib.
In two treated patients, symptoms, fecal calprotectin, and body weight improved within 4 weeks. The report provides no broader prescribing guidance.
Clinical Best Practices
- Interpret the study findings as evidence of multiple intestinal inflammatory changes; B-cell and plasma-cell depletion alone did not explain the complication.
- Recognize that mucosal CAR T-cell infiltration was not detected in every reported case.
- The researchers state that prospective sampling before CAR T-cell infusion is needed to better establish causality and assess potential treatment targets.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
